Q1 results include 14% sales growth and adjusted EPS of $.84; $.47 reported EPS Company raises sales guidance to low-double-digit growth and adjusted EPS to $3.30 to $3.40 for 2007
INDIANAPOLIS, Ind., April 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the first quarter of 2007 and raised its full-year sales and adjusted earnings per share guidance.

First-Quarter Highlights
* Sales increased 14 percent, to $4.226 billion.
* Products launched this decade -- Alimta®, Byetta®, Cialis®,
Cymbalta®, Forteo®, Strattera®, Symbyax®, Xigris® and
Yentreve® -- collectively grew 57 percent, to $1.259 billion, and
accounted for 30 percent of total sales, compared with 22 percent of
total sales in the first quarter of 2006.
* Reported net income and earnings per share were $508.7 million and $.47,
respectively, compared with first-quarter 2006 net income of $834.8
million and earnings per share of $.77. Reported results include
in-process research and development charges associated with the ICOS
acquisition and OSI in-licensing agreement and restructuring charges
associated with previously announced manufacturing decisions.
* Excluding these charges, adjusted net income and earnings per share both
grew 9 percent, to $913.3 million and $.84, respectively.
* On a pro forma basis, assuming the ICOS acquisition was completed
January 1, 2006, sales growth for the first quarter was 11 percent,
while adjusted net income and earnings per share both grew 14 percent,
to $901.9 million and $.83, respectively. Additional pro forma
information is provided later in this press release.

zie voor meer op.
http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=237952